Multiple myeloma (MM) is a relatively common hematological malignancy characterized by the presence of lytic bone disease. 1 As part of the staging procedures of newly diagnosed myeloma, the skeletal survey is mandatory, while bone marrow magnetic resonance imaging (MRI) can give complementary information and is recommended for patients with normal conventional radiographs. 2 MRI is very sensitive in detecting bone marrow involvement. 3 Four MRI patterns of marrow involvement in myeloma have been recognized: (1) normal appearance of bone marrow despite minor microscopic plasma cell infiltration, (2) focal involvement, (3) diffuse involvement and (4) 'salt-and-pepper' pattern with innumerable small focal lesions (variegated pattern). [3] [4] [5] MRI pattern of bone marrow involvement correlated with prognosis in patients with MM who After 48 h, cells were exposed to PEITC (10mM) for 18 h and percentage of apoptotic nuclei was measured by cell permeabilization and staining with propidium iodide, in flow cytometry, as described. 6 (b) Adenoviral constructs were generated using the BD Adeno-X Expression Systems 2 (BD Biosciences-Clontech, Palo Alto, CA, USA). For AdhBAG3 construction, bag3 full-length cDNA from human brain was cloned in pDNR-CMV vector and the gene expression cassette was transferred to the Adenoviral Acceptor Vector pLP-Adeno-X-PRLS viral DNA, containing DE1/DE3 Ad5 genome, by Cre-loxP-mediated recombination. AdNull, devoid of bag3 cDNA, was used as a control. K562 were transduced with AdhBAG3 or with control AdNull using a multiplicity of infection of 100 (100 MOI); after 48 h cells were exposed to PEITC at the indicated concentrations for 18 h, then apoptosis was measured by flow cytometry. Graph depicts the percentages of apoptotic nuclei. Significance between two groups was calculated by Student's t-test. For western blot analysis, whole-cell lysates were obtained and analyzed for BAG3 content. GAPDH was assessed to verify equal loading conditions. (c) K562 were transfected with WT1 RNAi or a scrambled sequence; after 24 h cells were transduced with AdhBAG3 or AdNull and, after additional 24 h, exposed to PEITC (10 mM) for 18 h. The graph depicts the percentage increase in cell survival with respect to WT1 RNAi-treated cells.
Letters to the Editor received conventional therapies. [3] [4] [5] However, there are limited data on the prognostic role of MRI pattern of marrow involvement in myeloma patients who receive novel therapies, such as bortezomib or the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide.
Increased angiogenesis is implicated in the pathogenesis of both myeloma cell growth and myeloma bone disease. The microvessel density (MVD) in bone marrow trephine biopsies correlates with survival in myeloma patients. 6 The aim of this study was to evaluate the prognostic value of MRI pattern of marrow infiltration in newly diagnosed myeloma patients who receive novel agents and to explore possible correlations of MRI pattern with clinical and laboratory data, bone marrow angiogenesis, lytic bone disease and survival.
In all, 82 consecutive patients with MM at diagnosis, 77 with symptomatic and 5 with asymptomatic disease were studied. The characteristics of the patients are depicted in Table 1 . MRI of the spine was carried out at the time of diagnosis and before any treatment administration. T1-weighted (repetition time (TR)/ echo time (TE): 641/10, turbo factor: 4), short TI inversion recovery (STIR) (TR/TE/inversion time (TI): 2000/70/150) and contrast-enhanced T1-weighted sagittal MRIs of the thoracic and lumbar spine were obtained with a 1.5 T unit (Phillips Medical Systems, Eindhoven, the Netherlands). MRIs were analyzed for pattern of myelomatous involvement. Marrow involvement was characterized as focal when only focal areas of abnormal marrow were seen. A variegated pattern of involvement was considered to be present when innumerable tiny foci of marrow replacement on a background of uninvolved marrow were observed throughout the spine. A diffuse pattern was diagnosed when no areas of normal marrow were seen in the parts of the spine under examination.
Immunohistochemical identification of microvascular endothelial cells was carried out in the bone marrow trephine biopsies at the time of diagnosis using a human monoclonal antibody against CD34 (Dako A/S, Glostrup, Denmark) by two experienced pathologists at Â 400 magnification. In each biopsy sample, microvessels were counted in at least three independent hot spots per section and the MVD of a bone marrow specimen was calculated as the mean value of all independent readings and recorded as the number of microvessels per Â 400 field. The variability between the two pathologists for the microvessel counts was o5.0% ( ± 3.5%). A hot spot was defined as an area of neoplastic infiltration containing the highest number of microvessels representing the greatest increase in microvascularity. When the microvessel count was 1-2, angiogenesis was characterized as low grade, whereas intermediate-grade angiogenesis was defined by the presence of a microvessel count of 3-6 and high-grade angiogenesis by the presence of microvessel count X7. MVD was also evaluated in 10 patients with monoclonal gammopathy of undetermined significance who served as controls.
The presence of bone involvement at diagnosis was documented with conventional skeletal surveys. Patients were considered to have bone involvement if there were radiographic abnormalities consistent with MM bone disease, including osteoporosis, osteolytic lesions and fractures. A grading of bone morbidity into three groups according to the radiographic evaluation of the skeleton was made. Group A included patients with no lytic lesions or osteoporosis; group B included patients with one to three osteolytic lesions at different anatomical sites and group C included patients with more than three osteolytic lesions and/or a pathological fracture due to MM. We used the o3/43 as cutoff for bone lesions, as advanced bone disease includes more than three lytic lesions according to the DurieSalmon staging system.
An enzyme-linked immunosorbent assay was used for the detection of the following serum indices of bone metabolism and angiogenesis: (i) osteoclast stimulators (soluble receptor activator of nuclear factor-kB ligand (sRANKL), osteoprotegerin (OPG), osteopontin and macrophage inflammatory protein-1a (MIP-1a)), (ii) inhibitor of osteoblast function dickkopf-1 (Dkk-1), (iii) bone resorption markers (C-and N-terminal crosslinking telopeptide of collagen type-I (CTX and NTX, respectively) and tartrate-resistant acid phosphatase isoform-5b (TRACP-5b)), (iv) bone formation markers (bone-specific alkaline phosphatase (bALP) and osteocalcin (OC)) and (v) angiogenic cytokines (vascular endothelial growth factor (VEGF), VEGF-A, angiogenin (ANG), angiopoietin-1 (ANGP-1), angiopoietin-2 (ANGP-2) and basic fibroblast growth factor), according to the manufacturer's instructions as previously described. 7 Control samples were obtained from 36 healthy, age-(median age 65.5 years, range: 45-88) and gender-(19 male/17 female) matched individuals. Each control was examined to ensure that there was no evidence of osteoporosis, osteoarthritis or autoimmune disorder, no receipt of medication that could alter normal bone turnover during the last 6 months and no evidence of infection.
Mann-Whitney U-test was used to evaluate differences between patients and controls, whereas Kruskal-Wallis test estimated differences between MM patients. The w 2 -test was used for the estimation of correlations between categorical variables. Spearman's nonparametric correlation test was used to determine the relationship between the various serum indices. The Kaplan-Meier method was used to estimate overall survival with differences compared by the two-sided log-rank Abbreviations: bALP, bone-specific alkaline phosphatase; bFGF, basic fibroblast growth factor; CTX, C-terminal crosslinking telopeptide of collagen type-I; Dkk-1, dickkopf-1; MIP-1a, macrophage inflammatory protein-1alpha; MM, multiple myeloma; MRI, magnetic resonance imaging; ND, non-detectable; NTX, N-terminal crosslinking telopeptide of collagen type-I; OC, osteocalcin; OPG, osteoprotegerin; OPN, osteopontin; sRANKL, soluble receptor activator of nuclear factor-kB ligand; TRACP-5b, tartrate-resistant acid phosphatase isoform-5b; VEGF, vascular endothelial growth factor. Abbreviations: bALP, bone-specific alkaline phosphatase; bFGF, basic fibroblast growth factor; CTX, C-terminal crosslinking telopeptide of collagen type-I; Dkk-1, dickkopf-1; MIP-1a, macrophage inflammatory protein-1a; MRI, magnetic resonance imaging; ND, non-detectable; NTX, N-terminal crosslinking telopeptide of collagen type-I; OC, osteocalcin; OPG, osteoprotegerin; OPN, osteopontin; sRANKL, soluble receptor activator of nuclear factor-kB ligand; TRACP-5b, tartrate-resistant acid phosphatase isoform-5b; VEGF, vascular endothelial growth factor.
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test to identify potential prognostic factors. Reduced multivariate models were generated by stepwise elimination of the least significant variables in the multivariate analyses until only significant covariates remained. Results were defined as statistically significant when Po0.05; all P-values are two sided and confidence intervals refer to 95% boundaries. The study was conducted after approval by the ethics committee/institutional review board and informed consent was obtained from all patients before any intervention. MRI evaluation of the spine revealed that 34 (41%) patients had focal, 26 (31%) diffuse, 18 (22%) normal and 4 (4%) had a variegated pattern of marrow involvement. Low-grade angiogenesis, as assessed by MVD, was present in 32 (39%) patients, whereas 33 (40%) had intermediate-grade and 17 (20%) patients had high-grade angiogenesis. All monoclonal gammopathy of undetermined significance patients had low-grade angiogenesis. Angiogenesis was more pronounced in patients with diffuse compared with patients with focal or normal patterns. Altogether, 21 of 26 (80%) patients with a diffuse MRI pattern had intermediate or high-grade angiogenesis in bone marrow trephine biopsies in contrast to 14 of 34 (41%) patients with focal involvement (P ¼ 0.01) and 12 of 18 (66%) patients with a normal MRI pattern (P ¼ 0.037). Myeloma patients had increased serum levels of VEGF (Po0.001), VEGF-A (Po0.001), ANGP-2 (Po0.001) and basic fibroblast growth factor (P ¼ 0.001), and reduced ANGP-1/ANGP-2 ratio (Po0.01) compared with the respective levels of the healthy controls (Table 2) . Patients with diffuse pattern had increased ANG serum levels compared with controls (P ¼ 0.004) and borderline elevated serum ANG compared with patients with normal pattern (P ¼ 0.06). Myeloma patients with diffuse pattern had also higher levels of serum VEGF and VEGF-A compared with patients with normal (P ¼ 0.028 and P ¼ 0.006, respectively) and focal pattern (P ¼ 0.009 and Po0.01, respectively; Table 3 ). Patients with lytic bone disease (groups B þ C) had increased values of VEGF (median 390 pg/ml; range: non-detectable (ND)-1968 pg/ml; P ¼ 0.011) and ANG (median 270 ng/ml; range: 15-2233 ng/ml; P ¼ 0.032) compared to patients without bone disease (group A: median for VEGF 308 pg/ml (range: ND-802 pg/ml); median for ANG 211 ng/ml (range: 7.8-1100 ng/ml)).
On the basis of conventional radiography, 32 (39%) patients had no lytic lesions at diagnosis, whereas 11 (13%) patients had 1-3 lytic lesions and 39 (47%) patients had 43 lytic lesions and/or a pathological fracture. Only 7 of 18 (39%) patients with normal MRI pattern had osteolytic lesions on skeletal surveys in comparison with 54 of 64 (84%) patients with the other three MRI patterns (Po0.001). Patients with diffuse pattern had a higher incidence of grade C bone disease (18 of 26, 69%) compared with patients with focal (17of 34, 50%) or normal (4 of 18, 22%) patterns (w 2 -test P ¼ 0.033). Myeloma patients had increased levels of sRANKL (Po0.001), OPG (Po0.001), sRANKL/OPG ratio (P ¼ 0.004), NTX (Po0.001), CTX (Po0.001), TRACP-5b (Po0.001), Dkk-1 (P ¼ 0.01), and osteopontin (Po0.001) and borderline reduced levels of bALP (P ¼ 0.09) compared with the respective levels of healthy controls (Table 2) . Patients with normal MRI pattern showed no difference in terms of Dkk-1 and bone formation markers compared with controls. Patients with diffuse pattern of marrow involvement had reduced values of bone formation markers (OC and bALP, P ¼ 0.01 and Po0.001, respectively), whereas patients with focal pattern had only a borderline reduction of OC (P ¼ 0.09) compared with controls. Both diffuse and focal MRI patterns had increased Dkk-1 levels. In terms of markers of bone resorption, normal, focal and diffuse patterns had increased levels of NTX, CTX and TRACP-5b and increased levels of osteoclast stimulators sRANKL/OPG, MIP-1a and osteopontin. We found no differences among the different MRI patterns with regard to markers of bone remodeling, although diffuse pattern had a borderline increase of NTX compared with normal and focal patterns (P ¼ 0.1 and P ¼ 0.08, respectively).
Diffuse and variegated patterns of infiltration correlated with greater bone marrow plasma cell infiltration (P ¼ 0.043) and advanced disease stage (P ¼ 0.018; Figure 1a) . In all, 29 (35.4%) patients received first-line therapy with thalidomide-based regimens, whereas 16 (19.5%) received bortezomib-based therapies and 2 (2.4%) patients were given the combination of lenalidomide plus dexamethasone. All patients received a combination regimen that contained at least one novel antimyeloma agent (thalidomide, lenalidomide and/or bortezomib) at some point during the course of their disease. The median follow-up of the patients was 25 months (range: 1-116 months) and the median survival was 50 months. Patients with diffuse or variegated pattern had a median survival of 29 months Letters to the Editor (95% confidence interval: 21.04-36.95), patients with focal pattern had a median survival of 62 months (95% confidence interval: 29.34-94.65), whereas the median survival of patients with normal MRI pattern was not reached at the time of the study (P ¼ 0.009; Figure 1b ). Univariate analysis showed that MRI pattern (diffuse and variegated vs others), International Staging System (ISS) stage (II or III vs I), lactate dehydrogenase, CTX, Dkk-1 and ANGP-1 as dichotomous variables predicted for survival (Table 4a ). However, in multivariate analysis, only MRI pattern and ISS stage correlated independently with survival (Table 4b) . MRI pattern of marrow involvement provides important information for disease activity in patients with MM. Our study showed, for the first time in the literature, a connection between MRI patterns of marrow involvement and the extent of angiogenesis, as assessed by MVD in trephine biopsies and serum levels of angiogenic cytokines, especially VEGF, VEGF-A and ANG. Several studies have shown that abundant bone marrow angiogenesis is present in the majority of myeloma patients requiring therapy and affects treatment response and survival. Malignant plasma cells express VEGF-A and ANG to facilitate the angiogenetic process. VEGF (and especially its angiogenic isoform VEGF-A) and fibroblast growth factors are essential for the initiation of vascular development, whereas ANG, which binds to actin on endothelial cells and activates basal membrane proteases mediates cell adhesion, invasion and tube formation. We found increased levels of VEGF and VEGF-A in myeloma patients with diffuse MRI bone marrow pattern compared with patients with normal or focal pattern and a borderline increase of ANG in diffuse compared with normal pattern; only patients with diffuse pattern had increased ANG levels compared with healthy controls. The presence of increased angiogenesis, associated with a diffuse MM MRI pattern, is further supported by increased MVD in such patients; 80% of patients with diffuse patterns had either intermediate-or high-grade angiogenesis compared with 66% of patients with normal and 41% of patients with focal patterns who had elevated MVD values. As angiogenesis has a crucial role in the biology of MM and the survival of myeloma patients, 6 it was not surprising that patients with diffuse MRI pattern had inferior survival compared with patients with focal and normal MRI pattern (Figure 1b) . Our group has previously reported that diffuse MRI pattern is associated with poor overall survival in myeloma patients who were treated with conventional chemotherapy or high-dose therapy with stem cell support. 4 In this study, diffuse MRI pattern continues to have an independent prognostic value for inferior survival in patients who were treated with novel antimyeloma agents (that is, bortezomib or IMiDs). It is well established that bortezomib and IMiDs may overcome some adverse prognostic features of myeloma and increase overall survival and thus they are considered to date as the main antimyeloma agents used for MM therapy. The majority of our patients (57%) received a novel agent-based therapy as first-line treatment, although all patients received bortezomib and/or an IMiD at some stage of their disease course. In our multivariate model, ISS stage and MRI pattern of infiltration were the only independent prognostic factors in these patients, suggesting that MRI pattern of bone marrow involvement remains a strong predictor for survival in the era of novel antimyeloma agents. It is also important that the prognostic value of MRI pattern of infiltration is independent of other features of advanced disease such as ISS stage and high plasma cell infiltration, confirming the results of our previous study. 4 In this study, patients who had normal MRI pattern had a twofold lower incidence of presence of lytic lesions on conventional skeletal survey compared with all other patients and a threefold lower incidence of extensive lytic bone disease (grade C) compared with patients with diffuse pattern. When we looked at the serum markers of bone remodeling, we found that, although patients with normal MRI pattern had increased bone resorption, they had no difference in bone formation and Dkk-1 compared with controls. However, patients with diffuse pattern had increased levels of Dkk-1 and reduced levels of bone formation markers bALP and OC. Reduced bone formation is associated with extensive lytic bone disease in MM, although Dkk-1, a potent osteoblast inhibitor through Wnt signaling inhibition, is elevated in myeloma patients with ISS-3 stage compared with those with ISS-2 and ISS-1 disease and correlates with the extent of lytic bone disease. Thus, we may form the hypothesis that all patients with myeloma have increased bone resorption, but patients with normal pattern maintain a rather normal osteoblast function and thus they have lower incidence of lytic bone disease compared with other patterns.
Another interesting finding of this study is that patients with lytic disease had increased levels of VEGF-A and ANG compared with those who did not have lytic lesions. VEGF may also act as an osteoclast activator. Our group has recently shown that there is a strong correlation between angiogenesis and lytic disease in MM. MIP-1a expression by myeloma cells correlated with both lytic bone disease and MVD, supporting the hypothesis that myeloma cells produce MIPs to attract monocytes and macrophages into their microenvironment and enhance the production of osteoclast precursors and neovessels through interactions with macrophages, monocytes and marrow stromal cells. 8 In this study, we found increased MIP-1a levels in all MRI patterns (Tables 2 and 3 ). Thus, it seems that there is a strong link between myeloma cells, stromal cells (including osteoclasts and osteoblasts) and angiogenesis that supports the myeloma cell growth. The correlation between diffuse MRI pattern of marrow involvement with increased angiogenesis and extended bone disease further illustrates these complicated interactions.
In conclusion, our study provides strong evidence that diffuse MRI pattern of marrow involvement correlates with increased angiogenesis, adverse disease features and is independently associated with inferior survival in myeloma patients who were treated with novel agents, suggesting the use of more aggressive regimens for such patients. Our results highlight the important prognostic value of MRI in myeloma and support its routine use in myeloma patients.
